% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/advancedtrials.h.R
\name{advancedtrials}
\alias{advancedtrials}
\title{Advanced Clinical Trial Methods}
\usage{
advancedtrials(
  data,
  time_var,
  event_var,
  treatment_var,
  biomarker_var,
  interim_time_var,
  stratification_vars,
  design_type = "group_sequential",
  primary_endpoint = "overall_survival",
  statistical_test = "log_rank",
  alpha_spending = "obrien_fleming",
  beta_spending = "obrien_fleming",
  number_of_looks = 3,
  information_fractions = "0.5,0.75,1.0",
  efficacy_boundaries = "auto",
  adaptation_type = "sample_size_reestimation",
  adaptation_timing = 50,
  conditional_power_threshold = 0.3,
  ni_margin = 1.25,
  ni_margin_type = "hazard_ratio",
  overall_alpha = 0.025,
  overall_power = 0.8,
  expected_hr = 0.75,
  accrual_rate = 25,
  dropout_rate = 0.05,
  number_of_arms = 2,
  control_arm_sharing = TRUE,
  interim_arm_addition = FALSE,
  interim_arm_dropping = FALSE,
  biomarker_strategy = "all_comers",
  biomarker_prevalence = 0.3,
  futility_analysis = TRUE,
  stochastic_curtailment = FALSE,
  predictive_power_threshold = 0.1,
  interim_monitoring_plan = TRUE,
  operating_characteristics = TRUE,
  boundary_plots = TRUE,
  conditional_power_analysis = FALSE,
  predictive_power_analysis = FALSE,
  bias_adjustment = FALSE,
  multiplicity_adjustment = FALSE,
  simulation_runs = 10000,
  seed_value = 12345
)
}
\arguments{
\item{data}{the data as a data frame}

\item{time_var}{Time to primary endpoint (survival, progression, response)}

\item{event_var}{Event indicator (1=event, 0=censored)}

\item{treatment_var}{Treatment arm assignment (experimental vs control)}

\item{biomarker_var}{Biomarker for enrichment or stratification strategies}

\item{interim_time_var}{Calendar time of interim analysis}

\item{stratification_vars}{Variables for stratified randomization}

\item{design_type}{Advanced clinical trial design type}

\item{primary_endpoint}{Primary efficacy endpoint}

\item{statistical_test}{Statistical test for primary analysis}

\item{alpha_spending}{Alpha spending function for efficacy boundaries}

\item{beta_spending}{Beta spending function for futility boundaries}

\item{number_of_looks}{Total number of planned interim looks}

\item{information_fractions}{Information fractions for each analysis
(comma-separated)}

\item{efficacy_boundaries}{Custom efficacy boundaries or 'auto' for
spending function}

\item{adaptation_type}{Type of mid-trial adaptation}

\item{adaptation_timing}{Percentage of planned events for adaptation
decision}

\item{conditional_power_threshold}{Threshold for sample size re-estimation}

\item{ni_margin}{Non-inferiority margin (hazard ratio scale)}

\item{ni_margin_type}{Scale for non-inferiority margin}

\item{overall_alpha}{One-sided Type I error rate}

\item{overall_power}{Overall study power}

\item{expected_hr}{Expected treatment effect (hazard ratio)}

\item{accrual_rate}{Expected patient accrual rate}

\item{dropout_rate}{Annual patient dropout rate}

\item{number_of_arms}{Total number of treatment arms}

\item{control_arm_sharing}{Share control arm across comparisons}

\item{interim_arm_addition}{Allow adding arms during trial}

\item{interim_arm_dropping}{Allow dropping arms for futility}

\item{biomarker_strategy}{Biomarker-driven design strategy}

\item{biomarker_prevalence}{Prevalence of positive biomarker}

\item{futility_analysis}{Include formal futility testing}

\item{stochastic_curtailment}{Use stochastic curtailment approach}

\item{predictive_power_threshold}{Threshold for futility based on
predictive power}

\item{interim_monitoring_plan}{Generate detailed interim monitoring
guidelines}

\item{operating_characteristics}{Calculate design operating characteristics
via simulation}

\item{boundary_plots}{Generate efficacy and futility boundary plots}

\item{conditional_power_analysis}{Calculate conditional power at interim
analyses}

\item{predictive_power_analysis}{Calculate predictive power for study
completion}

\item{bias_adjustment}{Apply bias adjustment methods for adaptive designs}

\item{multiplicity_adjustment}{Apply multiplicity adjustment for multiple
arms/endpoints}

\item{simulation_runs}{Number of simulations for operating characteristics}

\item{seed_value}{Random seed for reproducible simulations}
}
\value{
A results object containing:
\tabular{llllll}{
\code{results$instructions} \tab \tab \tab \tab \tab a html \cr
\code{results$trial_design_summary} \tab \tab \tab \tab \tab a table \cr
\code{results$group_sequential_boundaries} \tab \tab \tab \tab \tab a table \cr
\code{results$adaptive_design_parameters} \tab \tab \tab \tab \tab a table \cr
\code{results$platform_trial_design} \tab \tab \tab \tab \tab a table \cr
\code{results$biomarker_strategy_results} \tab \tab \tab \tab \tab a table \cr
\code{results$operating_characteristics} \tab \tab \tab \tab \tab a table \cr
\code{results$interim_monitoring_guidelines} \tab \tab \tab \tab \tab a table \cr
\code{results$sample_size_calculations} \tab \tab \tab \tab \tab a table \cr
\code{results$futility_analysis_results} \tab \tab \tab \tab \tab a table \cr
\code{results$multiplicity_adjustment} \tab \tab \tab \tab \tab a table \cr
\code{results$regulatory_compliance} \tab \tab \tab \tab \tab a table \cr
\code{results$boundary_plot} \tab \tab \tab \tab \tab an image \cr
\code{results$operating_characteristics_plot} \tab \tab \tab \tab \tab an image \cr
\code{results$conditional_power_plot} \tab \tab \tab \tab \tab an image \cr
\code{results$sample_size_sensitivity_plot} \tab \tab \tab \tab \tab an image \cr
\code{results$platform_trial_flowchart} \tab \tab \tab \tab \tab an image \cr
\code{results$design_recommendations} \tab \tab \tab \tab \tab a html \cr
}

Tables can be converted to data frames with \code{asDF} or \code{\link{as.data.frame}}. For example:

\code{results$trial_design_summary$asDF}

\code{as.data.frame(results$trial_design_summary)}
}
\description{
Advanced clinical trial methodologies including group sequential designs,
adaptive
trials, and interim monitoring. Provides sophisticated statistical methods
for
non-inferiority trials, futility analysis, and early stopping rules.
Implements
cutting-edge designs such as seamless Phase II/III, platform trials, and
master
protocol studies. Designed for clinical trialists requiring
state-of-the-art
methodology and regulatory compliance.
}
\examples{
data('clinical_trial')

advancedtrials(
    data = clinical_trial,
    time_var = "survival_time",
    event_var = "death",
    treatment_var = "arm",
    design_type = "group_sequential",
    alpha_spending = "obrien_fleming",
    number_of_looks = 3
)

}
